RestructuringJun 29, 2026, 07:11 AM
BioCryst Closes Discovery Center, Cuts 2026 OpEx Guidance
AI Summary
BioCryst Pharmaceuticals announced a strategic restructuring plan to discontinue its internal discovery programs and close its Birmingham, Alabama facility by the end of 2026. This move is part of an evolution to strengthen its rare disease pipeline through external innovation, leading to a reduction in its 2026 non-GAAP operating expense guidance to $420-$440 million from $450-$470 million. The company also reaffirmed its 2026 revenue guidance and provided updates on its clinical pipeline, including the completion of navenibart's Phase 3 enrollment and resolution of an ORLADEYO manufacturing delay.
Key Highlights
- Approved a plan to discontinue internal discovery programs and close the Discovery Center of Excellence facility in Birmingham, Alabama by end of 2026.
- Updated full year 2026 non-GAAP operating expense guidance to $420-$440 million, down from $450-$470 million.
- Reaffirmed full year 2026 ORLADEYO and total company revenue guidance.
- Completed enrollment in Phase 3 ALPHA-ORBIT for navenibart in June, with top-line data expected in Q3 2027.
- Proof-of-concept data for BCX17725 expected by year-end 2026.
- Resolved manufacturing delay of ORLADEYO oral pellets, with product availability expected in early August 2026.
Price Impact
More from BCRX